Austrianova FSG Biotechnologie GMBH
Austrianova is pursuing both cell- and retroviral gene-therapy technologies to treat cancer. The Vienna-based company's most advanced project is a cell-therapy designed to treat pancreatic cancer which has gained Orphan Drug status in Europe.
You may also be interested in...
Is gene therapy ever going to become a routine, reliable method of disease treatment? It appears that the odds of success in anything like the near term are slimming. Now one of the first companies to get involved in gene therapy is finally giving up on it: San Diego-based Vical Inc., founded in 1987, recently announced its intention to use its naked DNA technology to develop a vaccine for cytomegalovirus (CMV).
The criticism of gene therapy has been continual and consistent. But in fact, at least some delivery systems do work. It is true, however, that not all vectors work in all diseases, and the challenge for gene delivery start-ups is figuring out which ones work where.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.